Abbott Laboratories (ABLD.XC)
Cboe UK - Cboe UK Real-time price. Currency in EUR
Add to watchlist
At close: 03:29PM BST
| Previous close | 99.42 |
| Open | 99.42 |
| Bid | 98.10 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 99.42 - 99.42 |
| 52-week range | 87.58 - 104.98 |
| Volume | |
| Avg. volume | 2 |
| Market cap | 172.954B |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | 33.25 |
| EPS (TTM) | 2.99 |
| Earnings date | 18 Jul 2024 - 22 Jul 2024 |
| Forward dividend & yield | 2.07 (2.08%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
ZacksInvestors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
© 2024 Yahoo. All rights reserved.